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Introduction: To compare dynamic volume perfusion computed 
tomography (dVPCT) parameters with Response Evaluation Criteria 
in Solid Tumors (RECIST 1.1) for prediction of therapy response and 
overall survival (OS) in non–small-cell lung cancer (NSCLC) and 
small-cell lung cancer (SCLC) patients treated with conventional 
chemotherapy.
Methods: A total of 173 lung cancer patients (131 men; 61 ± 10 
years) undergoing dVPCT before (T1) and after chemotherapy (T2) 
and follow-up were prospectively included. dVPCT-derived blood 
flow, blood volume, mean transit time, and permeability (PERM) 
were assessed, compared between NSCLC and SCLC and patients’ 
response to therapy was determined according to RECIST 1.1.
Results: One hundred of one hundred and seventy-three patients 
underwent dVPCT at T1 and T2 within a median of 44 (range, 31–
108) days. dVPCT values were differing in NSCLC and SCLC, but 
were not significantly differing between patients with partial response, 
stable, or progressive disease. Eighty-five patients (NSCLC = 72 and 
SCLC = 13) with a follow-up for greater than or equal to 6 months 
were analyzed for OS. Fifty-six of eighty-five patients died during 
follow-up. Receiver operating characteristic analysis determined T1/
T2 with highest predictive values regarding OS for blood flow, blood 
volume, mean transit time, and permeability (area under the curve: 
0.53, 0.61, 0.54, and 0.53, respectively, all p > 0.05). Kaplan–Meier 
statistics revealed OS of patient groups assigned according to dVPCT 
T1/T2 cutoff values was not differing for neither dVPCT parameter, 
whereas RECIST groups significantly differed in OS (p = 0.02). 
Cox proportional hazards regression determined progressive disease 
status to independently predict OS (p = 0.004), while none of the 
dVPCT parameters did so.
Conclusions: dVPCT values, differ between NSCLC and SCLC, 
are not related to RECIST 1.1 classification and do not improve 
OS prediction in lung cancer patients treated with conventional 
chemotherapy.
Key Words: Dynamic volume perfusion computed tomography, 
Lung cancer, RECIST 1.1, Tumor response, Survival.
(J Thorac Oncol. 2015;10: 164–171)
Lung cancer is still the leading cause of cancer-related death worldwide with more than 1.5 million cases per year.1 
Continuous efforts are undertaken to improve diagnostic algo-
rithms, therapeutic monitoring, and follow-up for this huge 
patient group. Functional imaging techniques like dynamic 
perfusion computed tomography (dPCT) have been histo-
pathologically validated2,3 and proposed as complementary 
imaging biomarkers for the assessment of therapy response 
and prediction of outcome in addition to mere morphologi-
cal imaging techniques for different tumor entities.3–12 dPCT 
parameters are based on the analysis of time–density curves 
acquired with multiple repetitive computed tomography (CT) 
scans that start after the injection of a bolus of iodinated con-
trast material. Until recently, the biggest drawback of dPCT 
was the fact that time–density curves could only be acquired 
for selected transverse sections within the tumors but not for 
the whole tumor volume, limiting its representative value for 
response to therapy, especially in large heterogenous tumor 
masses.13 Reproducibility of dPCT values was further reduced 
due to tumor motion during the breathing cycle and, as a pos-
sible consequence, differing transverse tumor sections evalu-
ated in different intraindividual follow-up examinations.14
These limitations have been overcome with the advent 
of dPCT of whole tumor volumes with sufficient motion cor-
rection, subsequently referred to as dynamic volume perfu-
sion CT (dVPCT).15,16 In a previous study of our group that 
was published by Shi et al.17 in 2013, we evaluated functional 
dVPCT values of patients with advanced non–small-cell lung 
cancer (NSCLC) and small-cell lung cancer (SCLC) before 
treatment with regard to their independence from morpho-
metric parameters used for Response Evaluation Criteria in 
Solid Tumors (RECIST 1.1) response assessment. We could 
DOI: 10.1097/JTO.0000000000000376
Copyright © 2014 by the International Association for the Study of Lung Cancer
ISSN: 1556-0864/15/1001-0164
Dynamic Volume Perfusion Computed Tomography 
Parameters versus RECIST for the Prediction of Outcome 
in Lung Cancer Patients Treated with Conventional 
Chemotherapy
Sonja Sudarski, MD,* Jingyun Shi, MD,† Gerald Schmid-Bindert, MD,‡ Christian Manegold, MD,‡ 
Lothar R. Pilz, MA,§ Caicun Zhou, MD,║ Stefan O. Schoenberg, MD,* and Thomas Henzler, MD*
*Institute of Clinical Radiology and Nuclear Medicine, ‡,§Thoracic Oncology, 
Department of Surgery, University Medical Center Mannheim, Medical 
Faculty Mannheim, Heidelberg University, Germany; †Department of 
Radiology and ║Department of Medical Oncology, Shanghai Pulmonary 
Hospital, Tongji University School of Medicine, P. R. China.
Disclosure: The authors declare no conflict of interest.
Address for correspondence: Jingyun Shi, MD, Department of Radiology, 
Shanghai Pulmonary Hospital, Tongji University School of Medicine, 
No 507 Zhengmin Road, Shanghai 200433, P. R. China. E-mail: 
shijingyun89179@126.com
ORIGINAL ARTICLE
165Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 1, January 2015 Dynamic Volume Perfusion CT Parameters
demonstrate that dVPCT values were only partially related to 
tumor diameter and volume, suggesting a possible additional 
value for assessment of response and outcome beyond mere 
morphological assessment of conventionally applied tumor 
response criteria like World Health Organization and RECIST 
1.1.18 Previous work performed by other groups investigated 
the value of pre- and post-treatment dVPCT parameters with 
regard to response and progression-free survival in cohorts not 
exceeding 50 patients mostly in NCSLC.18–21 To the best of our 
knowledge, the prognostic value of dVPCT values in patients 
with advanced NSCLC as well as SCLC treated solely with 
conventional chemotherapy has not been investigated so far. 
The aim of this study was therefore to investigate the value of 
ratios resulting from dVPCT-derived baseline measurements 
and follow-up measurements after therapy in comparison to 
the RECIST 1.1 classification for the prediction of response to 
therapy and for the prognostic value regarding overall survival 
(OS) in patients with advanced NSCLC and SCLC treated 
with conventional chemotherapy. Furthermore, differences 
in dVPCT values between NSCLC and SCLC were assessed. 
This article is meant as a follow-up study of the patient cohort 
initially presented in the aforementioned study by Shi et al. 
Therefore, the authors are using the baseline dVPCT mea-
surements presented there for calculation of dVPCT ratios of 
patients within the cohort having undergone dVPCT scanning 
before and after chemotherapy. However, in clear distinction 
to this previous work, the actual study focuses on the pos-
sible coherence of these ratios with the RECIST classification 
regarding their predictive value in response assessment, and 
on the ratios’ prognostic value with regard to OS. In analogy 
to the first study, possible differences between tumor histolo-
gies were investigated in this article as well, yet not in such 
detail as previously (SCLC, adenocarcinoma [AC], and squa-
mous cell carcinoma), but only for SCLC and NSCLC, and 
with the new intention to evaluate consistency of the observed 
differences in the baseline dVPCT measurements with the 
measurements after therapy.
PATIENTS AND METHODS
Patient Inclusion Criteria
This prospective single-center study was approved by 
the institutional review board and complies both with the 
Declaration of Helsinki and the Health Insurance Portability 
and Accountability Act. Informed consent was obtained from 
all participating patients. Patients were included in the study 
if they fulfilled all of the following criteria: (1) nonresect-
able tumor with a minimum transverse diameter of 10 mm; 
(2) no previous chemotherapy or radiation treatment; and (3) 
histologically confirmed diagnosis from tissue of the tumor. 
The histological diagnosis was based on criteria of the World 
Health Organization.22 Tumor stage was determined according 
to the 7th edition of the TNM classification of lung cancer and 
recorded in all patients.23 A priori exclusion criteria were a his-
tory of contrast material reaction and impaired renal function 
(creatinine higher than 1.5 mg/dl and/or glomerular filtration 
rate lower than 60 ml/min), as well as tumors with a size larger 
than 96 mm in the z axis of the patient assessed at baseline CT 
scan. Furthermore, patients who received oncologic treatment 
with antiangiogenic substances at any time point of the study 
were excluded a posteriori from the analysis.
Dynamic Volume Perfusion CT Protocol
All studies were supervised by an experienced radiolo-
gist (J.S.) with 5 years of experience in thoracic radiology. 
All studies were performed on a 128-slice MDCT system 
(SOMATOM Definition AS+, Siemens Healthcare Sector, 
Forchheim, Germany). Initially, an unenhanced chest CT 
exam was performed to localize the tumor (120 kV; 180 mA; 
128 × 0.6 mm acquisition; 0.5 s rotation time; slice width 
5 mm). The supervising radiologist identified the location of 
the tumor and selected a fixed scan range of 96 mm in z axis 
for the dVPCT to cover the entire tumor. For perfusion imag-
ing, 50 ml of iopamidol (370 mg/ml iodine; Bracco, Shanghai, 
China) were injected through an 18-gauge needle in a cubital 
vein with a flow rate of 5 ml/s, followed by a saline chaser 
of 30 ml with identical flow rate (Dual-head power injector; 
Ulm, Germany).
dVPCT imaging was performed in a mid-exhalation 
breath hold with a 2 s delay after the injection. The dVPCT 
acquisition protocol (Adaptive 4D Spiral) consisted of 
30 scans with a 1.5 s temporal sampling (80 kV; 120 mA; 
32 × 1.2 mm collimation; 0.3 s rotation time). Images were 
reconstructed at a slice thickness of 3 mm and a 2 mm incre-
ment with a medium smooth kernel (B20). All patients were 
instructed to hold their breath for the whole scan period in a 
mid-exhalation state. If breath hold was not possible through-
out the scan, patients resumed shallow breathing.
The dose length product of this volume perfusion CT 
protocol has been estimated as 643 mGy ·cm resulting in an 
estimated effective dose of about 9 mSv using a chest-specific 
conversion coefficient of 0.014 mSv/Gy/cm.24
Image Postprocessing and Analysis
One radiologist (J.S.) with 5 years of experience in 
thoracic radiology analyzed all CT datasets. All datasets were 
transferred to a commercially available stand-alone worksta-
tion (MMWP, VE40A, Siemens Healthcare Sector) and pro-
cessed by its Volume Perfusion CT Body software. Dynamic 
data were corrected for motion with an integrated nonrigid 
registration technique. A volume of interest was then defined 
manually on morphological images (time maximum intensity 
projection), including the entire tumor while avoiding lym-
phangitis or pleural malignant fibrosis described as nonsolid 
irregularities of the surrounding parenchyma. Bones, air, and 
calcifications were subsequently excluded by application of a 
threshold-based segmentation algorithm including solely vox-
els between −50 and 150 HU at baseline scan. Vessels were 
excluded from calculation adjusting a threshold on a visual 
basis on a time maximum intensity projection image. A cir-
cular region of interest was placed into the thoracic aorta to 
measure the arterial input function. Color-coded parameter 
maps were subsequently calculated on the basis of a decon-
volution model. Values for the dVPCT parameters blood flow 
(BF: ml/100 ml/min), blood volume (BV: ml/100ml), mean 
transit time (MTT: s), and permeability (PERM: ml/100 ml/
min) were assessed.25 With regard to conventional response 
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assessment, patients were classified as complete remission, 
partial remission, stable disease (SD), and progressive dis-
ease (PD) according to revised RECIST 1.1 on the basis of 
morphological evaluation of the conventional sequences being 
acquired along with dVPCT datasets at T1 and T2.
Statistical Analysis
Statistical analysis was performed using dedicated soft-
ware (SAS 9.2, SAS Institute, Inc., Cary, NC), JMP 10.0 (SAS 
Institute), and MedCalc 13.0 (MedCalc Software, Ostend, 
Belgium). χ2 test for independence was performed a priori to 
further analyses to assess possible dependencies between cate-
gorical variables. Kolgorov–Smirnoff testing was performed to 
assess normal distribution for continuous variables. Categorical 
variables are presented as counts or percentages. Continuous 
variables are presented as median, 25th to 75th percentile, as 
well as minimum and maximum. The results of receiver operat-
ing characteristic analysis are given as area under the curve with 
95% confidence intervals (CIs). Comparisons were performed 
with two-sided unpaired or pairwise Wilcoxon rank sum test-
ing. Kaplan–Meier analysis was used to estimate patients’ OS: 
hazard ratios with 95% CIs and log-rank test were calculated to 
determine significant differences in survival rates between the 
groups. Right-censored data of patients who were alive at the 
last follow-up date are indicated in the graphs. A Cox propor-
tional hazards regression model was set up to determine pos-
sible independent predictors of the dependent variable of death 
or OS. Covariates were entered into the model stepwise and 
excluded if p value was greater than 0.1. The level of signifi-
cance was generally set to less than 0.05 and p value correction 
owing to multiple testing was performed if necessary.
RESULTS
Patient Characteristics
Between April 2011 and August 2011, 214 consecutive 
patients were screened for possible participation, out of which 
173 patients had previously untreated and histologically con-
firmed advanced lung cancer, fit the other inclusion and exclu-
sion criteria, and underwent baseline dVPCT scan before their 
first chemotherapy. Sixty-nine patients were lost to follow-up 
for a second dVPCT examination after two cycles of chemo-
therapy (Fig. 1). Four patients had to be excluded a posteriori 
from the analysis because they received a chemotherapeutic 
regimen including antiangiogenic substances. Consequently, a 
total of 100 patients, 84 with NSCLC and 16 with SCLC, treated 
with conventional chemotherapy underwent dVPCT at both T1 
and T2 within a median time span of 44 (25th to 75th percen-
tile: 40–52; range, 31–108) days. No dropouts due to failure of 
the study scan (e.g., contrast material extravasation due to high 
flow rate) or postprocessing was reported. The median overall 
follow-up time was 424 (229–601; 18–820) days. Eighty-five 
patients were followed up for greater than or equal to 6 months. 
Detailed patient characteristics are displayed in Table 1.
214 consecutive patients screened for possible study inclusion
- 28 patients who had received previous chemotherapies
- 10 patients who were ultimately diagnosed non-lung cancer, e.g. tuberculosis
- 3 patients who were excluded from the study because of impaired renal function
= 173 patients with untreated histologically proven advanced lung cancer fulfilling all study
inclusion and exclusion criteria underwent baseline dVPCT scan T1 prior to conventional
chemotherapy
- 69 patients who did not receive a second dVPCT scan in the facility after two
cycles of conventional chemotherapy (final decision for radiotherapeutic
treatment (9), refusal of participation (29), scanning for response assessment at 
different time points than after two cycles (11), deterioration of the general 
condition making the dVPCT scan impossible (13) , death of heart failure, 
pulmonary infection and stroke (7)) 
- 4 patients whose final therapeutic regime also included anti-
angiogenic substances, (a-posteriori exclusion)
= 100 patients undergoing follow-up dVPCT scan T2 
after two cycles of conventional chemotherapy
-> 100 patients undergoing follow-up of a 
median of 424 (18 to 820) days.
-> 85 patients undergoing follow-
up ≥ 6 months
FIGURE 1.  Overview of study patient selection.
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Treatment and Outcomes
Conventional chemotherapy regimens consisted mostly 
of standard platinum-based doublet therapy. Most patients 
with SCLC (13 of 16) received cisplatin or carboplatin plus 
etoposide. Two patients received etoposide monotherapy and 
one patient received irinotecan plus cisplatin. Most patients 
with NSCLC (64 of 84) received a combination of cisplatin, 
oxaplatin or carboplatin plus gemcitabine or vinorelbine. Four 
patients with squamous cell carcinoma (SCC) received gem-
citabine monotherapy and four patients received carboplatin 
plus paclitaxel. One SCC patient received docetaxel mono-
therapy. Concerning the patients with AC, seven patients 
received carboplatin–cisplatin plus paclitaxel and four patients 
received vinorelbine or gemcitabine monotherapy.
Treatment outcomes were classified according to revised 
RECIST 1.1 classification26 (Supplementary Figure, SDC 1, 
http://links.lww.com/JTO/A723). Seventeen of one hundred 
patients were classified as partial remission, 73 of 100 patients 
as SD, and 10 of 100 patients as PD. None of the patients was 
classified as complete remission.
dVPCT Measurements
Analyzing all 100 patients, overall pretherapeutic 
dVPCT values were significantly higher compared with post-
therapeutic values for MTT (9.71 versus 9.65 s, p = 0.007) 
and PERM (18.5 versus 16.6 ml/100 ml/min, p = 0.009). In 
BF and BV, pre- and post-therapeutic dVPCT values were not 
significantly differing (Supplementary Table, SDC 2, http://
links.lww.com/JTO/A724).
The dVPCT values of BF, BV, MTT, and PERM at T1 
and T2 are displayed for patients being divided into response 
groups according to RECIST 1.1 (Table 2). Changes in dVPCT 
parameters were tested for independence of morphological 
tumor response categories by means of paired Wilcoxon rank 
sum test for T1 and T2 separately: none of the dVPCT param-
eters were correlated to a specific response category (Table 2). 
Regarding T1/T2 ratios, no significant differences between 
dVPCT values of RECIST 1.1 response groups were observed 
either (Supplementary Table, SDC 3, http://links.lww.com/
JTO/A725). Comparison of dVPCT values between patients 
with NSCLC and SCLC are presented in Table 3: Except for 
BF, dVPCT values significantly varied between histological 
subgroups regarding either values of T1, T2, T1/T2, or all three. 
Differences between dVPCT values at T1 compared with T2 
concerning BF, BV, MTT, and PERM are also displayed sepa-
rately for patients with NCSLC and SCLC (Supplementary 
Table, SDC 4, http://links.lww.com/JTO/A726) and revealed 
that in NSCLC patients, pre- and post-therapeutic values of BF, 
BV, MTT, and PERM were not significantly differing, whereas 
with regard to SCLC patients MTT was significantly different 
at T1 and T2 (10.3 versus 8.3 s, p = 0.0005).
Receiver operating characteristic analysis solely includ-
ing patients with a follow-up time of greater than or equal to 6 
months determined the highest predictive value with regard to 
decreased OS for dVPCT T1/T2 ratios greater than 0.73 for BF, 
greater than 0.92 for BV, greater than 1.02 for MTT, and less 
than or equal to 1.24 for PERM with area under the curve values 
of 0.53 (95% CI: 0.42–0.64), 0.61 (95% CI: 0.50–0.72), 0.54 
(95% CI: 0.43–0.65), and 0.53 (95% CI: 0.42–0.64), respec-
tively (p values for BF, BV, MTT, and PERM: 0.71, 0.09, 0.52, 
and 0.69, respectively). Fifty-six patients died in the course of 
follow-up. Kaplan–Meier statistics separating patients into two 
groups according to each of the single determined T1/T2 cutoff 
values for BF, BV, MTT, and PERM were all not statistically 
significant (log-rank tests: all p > 0.05), Figure 2A–D.
When patients were divided into three groups according 
to their RECIST 1.1 status, survival was predicted with hazard 
ratios of 3.08 (95% CI: 0.90–10.49) for PR versus PD, 2.58 (95% 
CI: 0.84–7.93) for SD versus PD, and 1.20 (95% CI: 0.62–2.30) 
for PR versus SD; log-rank test, p = 0.02 (Fig. 3). Median sur-
vival for patients with PD, SD, and PR was 9 (95% CI: 7–14), 16 
(95% CI: 13–19), and 18 (95% CI: 11–19) months, respectively.
Including RECIST 1.1 response groups, histology, 
patients’ age at time point of first dVPCT scan, tumor stage 
and T1/T2 of BF, BV, MTT, and PERM as covariates in the 
Cox proportional hazards model, solely age (p = 0.03; hazard 
ratio: 1.04; 95% CI: 1.01–1.07), presence of T3 stage tumor 
(p = 0.02; hazard ratio: 3.26; 95% CI: 1.45–7.35), and PD 
RECIST 1.1 status (p = 0.003; hazard ratio: 3.38; 95% CI: 
1.54–7.42) were revealed as independent predictors of survival.
TABLE 1.  Patients Characteristics Grouped According to RECIST 1.1 Classification
PR (n = 17) SD (n = 73) PD (n = 10) All (n = 100)
Age Median 62.2 62.2 53.2 61.5
Range 51.6–75.0 39.8–81.5 42.8–72.8 39.8–81.5
Histology NSCLC 12 (71%) 64 (88%) 8 (80%) 84 (84%)
  AC 8 (47%) 46 (63%) 2 (20%) 56 (56%)
  SCC 4 (24%) 18 (25%) 6 (60%) 28 (28%)
SCLC 5 (29%) 9 (12%) 2 (20%) 16 (16%)
Gender Female — 14 (19%) — 14 (14%)
Male 17 (100)% 59 (81%) 10 (100%) 86 (86%)
Tumor stage IIIa 2 (12%) 5 (7%) 1 (10%) 8 (8%)
IIIb 5 (29%) 22 (30%) 3 (30%) 30 (30%)
IV 10 (59%) 46 (63%) 6 (60%) 62 (62%)
RECIST, Response Evaluation Criteria in Solid Tumors; AC, adenocarcinoma; PD, progressive disease; PR, partial response; SCC, squamous cell carcinoma; SD, stable disease; 
NSCLC, non–small-cell lung cancer; SCLC, small-cell lung cancer.
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TABLE 2.  Differences in dVPCT Parameters Between RECIST 1.1 Response Groups at Time Points Before (T1) and After (T2) 
Treatment
Response Group Median Test (X/Y) EST M(X)−M(Y) 95% CI p Value Significance
Blood flow T1 PR, N = 17 71.6 PR/SD 7.400 −4.120 to 18.340 0.206676 NS
SD, N = 73 66.5 PR/PD 7.385 −7.450 to 20.450 0.263850 NS
PD, N = 10 64.7 SD/PD −0.710 −14.720 to 13.190 0.866686 NS
Blood flow T2 PR, N = 17 71.5 PR/SD 3.09 −13.420 to 17.260 0.699083 NS
SD, N = 73 63.6 PR/PD 7.05 −11.570 to 22.900 0.536954 NS
PD, N = 10 64.5 SD/PD 1.18 −13.430 to 22.560 0.888746 NS
Blood volume T1 PR, N = 17 9.25 PR/SD 0.74 −0.76 to 2.31 0.317356 NS
SD, N = 73 8.88 PR/PD 0.25 −1.99 to 2.57 0.711452 NS
PD, N = 10 8.86 SD/PD −0.25 −2.55 to 1.25 0.664529 NS
Blood volume T2 PR, N = 17 8.41 PR/SD −0.830 −2.760 to 1.320 0.483325 NS
SD, N = 73 9.11 PR/PD 0.135 −2.820 to 3.100 0.941071 NS
PD, N = 10 8.03 SD/PD 0.780 −1.490 to 3.140 0.519899 NS
Mean transit time T1 PR, N = 17 9.1 PR/SD −0.08 −1.14 to 0.82 0.893395 NS
SD, N = 73 9.7 PR/PD −0.48 −1.59 to 0.70 0.359470 NS
PD, N = 10 10.2 SD/PD −0.29 −1.48 to 1.08 0.604728 NS
Mean transit time T2 PR, N = 17 7.76 PR/SD −1.18 −2.75 to 0.35 0.103369 NS
SD, N = 73 9.76 PR/PD −0.93 −3.52 to 0.78 0.223054 NS
PD, N = 10 8.98 SD/PD 0.14 −1.67 to 2.03 0.828337 NS
Permeability T1 PR, N = 17 18.6 PR/SD −0.30 −3.54 to 2.96 0.873056 NS
SD, N = 73 18.3 PR/PD 0.01 −5.18 to 3.73 1.000000 NS
PD, N = 10 17.6 SD/PD −0.15 −2.85 to 2.79 0.933108 NS
Permeability T2 PR, N = 17 13.7 PR/SD −3.060 −6.670 to 0.570 0.102288 NS
SD, N = 73 17.8 PR/PD −1.375 −6.570 to 4.150 0.570149 NS
PD, N = 10 16.3 SD/PD 1.490 −2.460 to 5.640 0.466959 NS
p value approximative, tie corrected (Cureton and Kendall).
dVPCT, dynamic volume perfusion computed tomography; NS, non-significant; RECIST, Response Evaluation Criteria in Solid Tumors; PD, progressive disease; PR, partial 
response; SD, stable disease; T1, time point of first dVPCT; T2, time point of second dVPCT (N = 100).
TABLE 3.  Differences in dVPCT Parameters at T1, T2 for T1/T2 Values Comparing Histological Subgroups
NSCLC (N = 84) SCLC (N = 16)
Median (X) Median (Y) EST M(X)−M(Y) 95% CI p Value Significance
Blood flow T1 68.4 58.0 9.2 −1.2 to 20.2 0.08032 −
Blood flow T2 65.7 61.1 9.9 −3.9 to 24.8 0.14245 −
Blood volume T1 8.95 8.62 0.7 −0.6 to 2.3 0.26319 −
Blood volume T2 9.5 6.4 2.8 1.2–4.6 0.00208 +
Mean transit time T1 9.64 10.29 −0.69 −1.64 to 0.34 0.17877 −
Mean transit time T2 9.9 8.3 1.6 0.5–3.0 0.00895 +
Permeability T1 18.9 16.1 3.7 1.0–6.5 0.00737 +
Permeability T2 17.6 12.3 5.3 1.8–8.4 0.00345 +
Blood flow T1/T2 0.987 0.954 −0.01 −0.24 to 0.18 0.92509 −
Blood volume T1/T2 0.96 1.22 −0.25 −0.43 to −0.07 0.00779 +
Mean transit time T1/T2 1.06 1.35 −0.26 −0.41 to −0.12 0.00211 +
Permeability T1/T2 1.05 1.17 −0.13 −0.38 to 0.13 0.31440 −
p value approximative, tie corrected (Cureton and Kendall).
dVPCT, dynamic volume perfusion computed tomography; NSCLC, non–small cell lung cancer; SCLC, small-cell lung cancer; T1, time point of first dVPCT; T2, time point of 
second dVPCT (N = 100).
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DISCUSSION
Accurate response assessment and outcome prediction in 
solid tumors that takes into consideration the pathophysiologi-
cal principles of conventional chemotherapy versus antiangio-
genic treatment—that is primarily cytotoxic versus cytostatic 
chemotherapy—is subject of ongoing intensive research efforts.
Fournier et al.10 assessed the additional value of dPCT-
derived functional measurements in comparison to RECIST 
response assessment for prediction of response to therapy, 
PFS and OS in 51 patients with metastatic renal cell carci-
noma receiving antiangiogenic therapy. Baseline perfusion 
parameters BF and BV were higher in responders than in 
stable patients, but were not significantly predictive of sur-
vival. After the first cycle of treatment, there was a significant 
decrease in BF and BV and the authors concluded that perfu-
sion CT correlates with RECIST but may be able to predict 
response to antiangiogenic therapy before treatment starts and 
to detect very early response to therapy.
Bellomi et al.5 investigated the use of perfusion CT for 
the monitoring of combined neoadjuvant chemotherapy and 
radiation therapy of AC of the rectum with regard to response 
assessment to therapy in a small cohort of 19 patients and 
found BF, BV, and PERM-surface area product to be signifi-
cantly decreased after therapy. Furthermore, baseline values 
of BF and BV in the seven patients who failed to respond 
to treatment were significantly lower than in the 17 respond-
ers, suggesting a correlation of RECIST response criteria and 
perfusion CT-derived measurements.
The results of this study demonstrate that dVPCT levels in 
NSCLC and SCLC patients before and after two cycles of con-
ventional chemotherapy do not correspond to tumor response 
categories based on RECIST 1. These results are in accordance 
to the study performed by our group investigating dVPCT base-
line values of the patient cohort followed up in this study, where 
tumor diameter was not correlated with any dVPCT parameter.17
Furthermore, differing dVPCT values have been 
observed for NSCLC and SCLC in this study except for BF, 
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FIGURE 2.  Kaplan–Meier curves separating patients with a minimum survival time greater than or equal to 6 months accord-
ing to the optimal T1/T2 cutoffs for survival prediction determined in ROC analysis for dVPCT-derived (A) blood flow (log-rank 
test: p = 0.28), (B) blood volume (log-rank test: p = 0.08), (C) mean transit time (log-rank test: p = 0.22), and (D) permeability 
(log-rank test: p = 0.37) (N = 85). Censored data of survivors at last follow-up date are indicated by vertical lines. ROC, receiver 
operating characteristic; dVPCT, dynamic volume perfusion computed tomography; BF, blood flow; BV, blood volume; T1, time 
point of first dVPCT; T2, time point of second dVPCT.
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whereas neither dVPCT levels at T1, T2 nor T1/T2 ratios were 
significantly varying between tumor subtypes. These results 
are differing from the analysis of the baseline dVPCT values 
published by Shi et al.,17 where solely MTT values were simi-
lar between histological subtypes. However, in the previous 
study, all 173 patients’ baseline dVPCT measurements were 
included and subgroup analysis was performed for the three 
histological subtypes of SCC, AC, and SCLC, what might 
explain disconcordance of the presented results.
Wang et al.27 investigated nonvolume dPCT performed 
with a 16-slice MDCT in a small cohort of solely patients with 
advanced NSCLC before and after chemoradiation therapy 
and found significantly higher baseline tumor BF in respond-
ers than in nonresponders (Supplementary Table, SDC 5, 
http://links.lww.com/JTO/A727). In our study, no significant 
differences in BF were observed between patients with PD, 
SD, and PR. Differing results may be explained by differ-
ing treatment modalities (chemotherapy versus chemoradio-
therapy), bias of nonvolume dPCT-derived BF values and by 
dividing patients into two instead of three response groups. 
Furthermore, findings in the above-mentioned study might 
have been confounded by the small patient number of n = 35.
In a study by Fraioli et al.,19 dVPCT parameters were 
investigated in patients with AC undergoing chemotherapy 
combined with antiangiogenic treatment (Supplementary 
Table, SDC 5, http://links.lww.com/JTO/A727). According to 
Fraioli, BF, BV, and PERM values were significantly higher in 
responders at second follow-up, whereas in the nonresponders, 
time to peak was higher. In our study, significant changes were 
not observed in any dVPCT parameter after two cycles of che-
motherapy comparing different RECIST response groups. Yet, 
in our study cohort, patients were solely treated with conven-
tional chemotherapy.
In a small follow-up study by Tacelli et al.,21 patients 
with NSCLC were investigated, being treated with either 
conventional chemotherapy or the antivascular endothelial 
growth factor bevacizumab (Supplementary Table, SDC 5, 
http://links.lww.com/JTO/A727). Patients underwent CT 
perfusion before and after one, three and six cycles of che-
motherapy. In the group with conventional chemotherapy, 
a significant reduction in perfusion was identified between 
baseline and all three follow-up perfusion CT scans without 
any significant change in the group with antiangiogenic treat-
ment. These results stand in contrast to our results, indicating 
no differences in pre- and post-therapeutic BF values.
Most of the previous studies suggest an additional 
value of dVPCT in tumor patients treated with antiangiogenic 
substances initially having brought up functional imaging 
and dPCT/dVPCT into the discussion.20 The study by Lind 
et al.20 investigated patients with advanced NSCLC receiving 
antiangiogenic (sorafenib) and antiendothelial growth factor 
receptor (erlotinib) treatment, and correlated tumor BF with 
treatment outcome (Supplementary Table, SDC 5, http://links.
lww.com/JTO/A727). The results suggested not only predic-
tive value of BF with regard to treatment response but also a 
possible advantage for prediction of progression-free survival.
The predictive value of functional/molecular imaging 
has been investigated with multiple modalities: Mileshkin 
et al.28 investigated 18F-fluorodeoxyglucose (FDG) and 
18F-fluorodeoxyxythymidine (FLT) positron emission tomog-
raphy (PET) in 51 patients with NSCLC undergoing erlo-
tinib therapy and found that 18F-FDG-PET-assessed partial 
metabolic response at day 14 was associated with improved 
progression-free survival as well as OS, even in the absence of 
RECIST measured tumor response.
Functional CT scans come along with an increase in 
radiation dose. Latest generation CT scanner systems are facing 
this problem with multiple dose-saving approaches like DECT-
derived virtual unenhanced datasets and denoising strategies 
for low-kV scanning like iterative reconstruction algorithms.29,30 
Therefore, in case of a clear proven additional benefit of dVPCT 
studies in the work-up of lung cancer patients or patients suffer-
ing from other malignancies, an easy inclusion of dynamic CT 
scans into staging and restaging CT protocols without exceeding 
reference dose values seems a realistic scenario in the near future.
Limitations
This study suffers from several limitations that have to 
be considered: A recent study evaluated two commercially 
available dVPCT software packages in patients with colorectal 
cancer and found that measurements were not directly compa-
rable between different mathematical algorithms for model-
ing of voxel-based time attenuation.31 Thus, our quantitative 
results based on the deconvolution model may not directly be 
comparable to dVPCT studies using different mathematical 
approaches as, for example, the maximum slope model, where 
half as high values for BF have been reported in comparison 
to the values calculated with the deconvolution model.2,20,32 
Yet, other work comparing deconvolution and maximum 
slope approach mathematical approaches curves in the assess-
ment of brain perfusion found resulting perfusion values to 
be comparable.25 Second, we did not assess inter and intrao-
bserver variability of dVPCT measurements; yet, this issue 
FIGURE 3.  Kaplan–Meier curves separating patients with a 
minimum survival time greater than or equal to 6 months into 
RECIST 1.1 response groups. Log-rank test: p = 0.02 (N = 85). 
Censored data of survivors at last follow-up date are indicated 
by vertical lines. PR, partial remission; PD, progressive disease; 
SD, stable disease.
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has been previously addressed by other groups with promising 
results.33,34 Third, baseline perfusion values have been reported 
to vary among histological lung cancer types.17,35 However, to 
ensure power of the survival analysis, no further histological 
subgroup analysis of patients was performed and this subject 
requires further investigation with larger patient cohorts.
CONCLUSION
Our data suggest that in patients with advanced NSCLC 
and SCLC, functional dVPCT parameters differ between 
histological subtypes. Furthermore, dVPCT values are not 
related to morphological response assessment according to 
RECIST 1.1 and do not improve prediction of OS in patients 
treated with conventional chemotherapy.
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